A Phase Ib Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biological Effect of MSC2364447C in Systemic Lupus Erythematosus
Phase of Trial: Phase I
Latest Information Update: 01 Dec 2016
At a glance
- Drugs Evobrutinib (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions
- Sponsors EMD Serono
- 28 Nov 2016 Status changed from recruiting to completed.
- 09 Aug 2016 Status changed from active, no longer recruiting to recruiting.
- 28 Jul 2016 Status changed from recruiting to active, no longer recruiting.